tiprankstipranks
Advertisement
Advertisement

RZLT Stock Latest News

Rezolute Prepares FDA Submission After sunRIZE Trial Review
Company AnnouncementsRezolute Prepares FDA Submission After sunRIZE Trial Review
19h ago
8K
RZLT
Rezolute provides update on sunRIZE study following Type B meeting with FDA
PremiumThe Fly
Rezolute provides update on sunRIZE study following Type B meeting with FDA
20h ago
RZLT
Rezolute management to meet with Maxim
PremiumThe Fly
Rezolute management to meet with Maxim
22d ago
RZLT
Rezolute: Positive Risk‑Reward Outlook Despite sunRIZE Miss, Backed by Encouraging Hyperinsulinism Data and Solid Cash Position
PremiumRatings
Rezolute: Positive Risk‑Reward Outlook Despite sunRIZE Miss, Backed by Encouraging Hyperinsulinism Data and Solid Cash Position
1M ago
RZLT
Rezolute reports Q2 EPS (22c), consensus (18c)
PremiumThe Fly
Rezolute reports Q2 EPS (22c), consensus (18c)
1M ago
RZLT
RZLT Earnings this Week: How Will it Perform?
PremiumPre-EarningsRZLT Earnings this Week: How Will it Perform?
1M ago
RZLT
Rezolute price target raised to $2 from $1 at Wedbush
Premium
The Fly
Rezolute price target raised to $2 from $1 at Wedbush
3M ago
RZLT
Maintaining a Buy on Rezolute: Clear Drug Activity, High-Need Patient Benefit, and Upcoming FDA Catalysts Support Attractive Risk-Reward
Premium
Ratings
Maintaining a Buy on Rezolute: Clear Drug Activity, High-Need Patient Benefit, and Upcoming FDA Catalysts Support Attractive Risk-Reward
3M ago
RZLT
Rezolute (RZLT): Mixed Phase 3 Data, Regulatory Uncertainty in Congenital HI, and Tumor HI Optionality Support Reiterated Hold Rating
PremiumRatings
Rezolute (RZLT): Mixed Phase 3 Data, Regulatory Uncertainty in Congenital HI, and Tumor HI Optionality Support Reiterated Hold Rating
3M ago
RZLT
Rezolute: Favorable Risk-Reward on Ersodetug Despite Mixed sunRIZE Data, Supported by Biomarkers, Breakthrough Designation, and Phase 3 Potential
PremiumRatings
Rezolute: Favorable Risk-Reward on Ersodetug Despite Mixed sunRIZE Data, Supported by Biomarkers, Breakthrough Designation, and Phase 3 Potential
3M ago
RZLT
Rezolute shares findings from Expanded Access Program in tumor HI
PremiumThe Fly
Rezolute shares findings from Expanded Access Program in tumor HI
3M ago
RZLT
Rezolute shares observations from Phase 3 sunRIZE study in congenital HI
PremiumThe Fly
Rezolute shares observations from Phase 3 sunRIZE study in congenital HI
3M ago
RZLT
Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans
PremiumCompany AnnouncementsRezolute Updates sunRIZE Phase 3 Trial and FDA Plans
3M ago
8K
RZLT
Rezolute price target lowered to $4 from $20 at Maxim
Premium
The Fly
Rezolute price target lowered to $4 from $20 at Maxim
3M ago
RZLT
Rezolute price target lowered to $6 from $15 at Guggenheim
Premium
The Fly
Rezolute price target lowered to $6 from $15 at Guggenheim
3M ago
RZLT
Rezolute price target lowered to $5 from $14 at H.C. Wainwright
PremiumThe Fly
Rezolute price target lowered to $5 from $14 at H.C. Wainwright
3M ago
RZLT
Rezolute downgraded to Hold from Buy at Craig-Hallum
PremiumThe Fly
Rezolute downgraded to Hold from Buy at Craig-Hallum
3M ago
RZLT
Rezolute price target lowered to $5 from $17 at BTIG
PremiumThe Fly
Rezolute price target lowered to $5 from $17 at BTIG
3M ago
RZLT
Rezolute downgraded to Market Perform from Outperform at Citizens
PremiumThe Fly
Rezolute downgraded to Market Perform from Outperform at Citizens
3M ago
RZLT
Rezolute downgraded to Neutral from Overweight at Cantor Fitzgerald
PremiumThe FlyRezolute downgraded to Neutral from Overweight at Cantor Fitzgerald
3M ago
RZLT
Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss
Premium
The Fly
Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss
3M ago
RZLT
Rezolute Downgraded to Hold Amid Disappointing Phase 3 Trial Results for Ersodetug
Premium
Ratings
Rezolute Downgraded to Hold Amid Disappointing Phase 3 Trial Results for Ersodetug
3M ago
RZLT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >